Dawson James Securities launched coverage of Know Labs (OTCQB:KNWN) with a “buy” rating and price target of $7. The stock closed at $1.59 on Feb. 7. “Know Labs is driving what could be a significant paradigm shift in...
Dawson James Securities upgraded Check-Cap (NASDAQ:CHEK) to “buy” from “neutral” and maintained its price target of $1. The stock closed at 60 cents on Feb. 4. The company’s C-Scan is a colorectal cancer screening test...
H.C. Wainwright initiated coverage of Inozyme (NASDAQ:INZY) with a “buy” rating and $33 price target. The stock closed at $6.10 on Feb. 4. Inozyme is a rare disease biopharmaceutical company focused on developing...
Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...
Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...
In an industry wide series of research reports, Maxim Group analyst Jason McCarthy, Ph.D., lowered price targets on stocks in his coverage universe, saying industry multiples have contracted but company outlooks remain...
Analysts for SVB Leerink and H.C. Wainwright launched coverage of Amylyx Pharmaceuticals (NASDAQ:AMLX) with “outperform” and “buy” ratings, and price targets of $50 and $35, respectively. The stock closed at $23.18 on...
Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...
Analysts for H.C. Wainwright and Cantor Fitzgerald raised their price targets for Checkpoint Therapeutics (NASDAQ:CKPT) to $26 and $20, respectively, after the company reported positive pivotal data with anti-PD-L1...
Stifel initiated coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and price target of $7, reflecting a multiple of 8.3 times estimated 2023 revenue of $130-million. The stock closed at $4.46 on Jan. 24. “We see...